{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T04:36:23Z","timestamp":1762144583655},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2007,12,19]],"date-time":"2007-12-19T00:00:00Z","timestamp":1198022400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmied Arch Pharmacol"],"published-print":{"date-parts":[[2008,2]]},"DOI":"10.1007\/s00210-007-0231-1","type":"journal-article","created":{"date-parts":[[2007,12,18]],"date-time":"2007-12-18T11:06:25Z","timestamp":1197975985000},"page":"431-440","source":"Crossref","is-referenced-by-count":14,"title":["Electrophysiological profile of propiverine \u2013 relationship to cardiac risk"],"prefix":"10.1007","volume":"376","author":[{"given":"Torsten","family":"Christ","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erich","family":"Wettwer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melinda","family":"Wuest","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manfred","family":"Braeter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank","family":"Donath","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pascal","family":"Champeroux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Serge","family":"Richard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ursula","family":"Ravens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2007,12,19]]},"reference":[{"key":"231_CR1","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1113\/jphysiol.1996.sp021194","volume":"491","author":"GJ Amos","year":"1996","unstructured":"Amos GJ, Wettwer E, Metzger F, Li Q, Himmel HM, Ravens U (1996) Differences between outward currents of human atrial and subepicardial ventricular myocytes. J Physiol 491:31\u201350","journal-title":"J Physiol"},{"key":"231_CR2","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/BF00586939","volume":"379","author":"D Atwell","year":"1979","unstructured":"Atwell D, Cohen I, Eisner D, Ohba M, Ojeda C (1979) The steady state TTX-sensitive (\u201cwindow\u201d) sodium current in cardiac purkinje fibres. Pflugers Arch 379:137\u2013142","journal-title":"Pflugers Arch"},{"key":"231_CR3","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1113\/jphysiol.2006.116012","volume":"576","author":"GC Bett","year":"2006","unstructured":"Bett GC, Morales MJ, Beahm DL, Duffey ME, Rasmusson RL (2006) Ancillary subunits and stimulation frequency determine the potency of chromanol 293B for the KCNQ1 potassium channel. J Physiol 576:755\u2013767","journal-title":"J Physiol"},{"key":"231_CR4","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/sj.bjp.0704881","volume":"137","author":"P Biliczki","year":"2002","unstructured":"Biliczki P, Virag L, Iost N, Papp JG, Varro A (2002) Interaction of different potassium channels in cardiac repolarization in dog ventricular preparations: role of repolarization reserve. Br J Pharmacol 137:361\u2013368","journal-title":"Br J Pharmacol"},{"key":"231_CR5","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1053\/euhj.2000.2222","volume":"21","author":"AJ Camm","year":"2000","unstructured":"Camm AJ, Janse MJ, Roden DM, Rosen MR, Cinca J, Cobbe SM (2000) Congenital and acquired long QT syndrome. Eur Heart J 21:1232\u20131237","journal-title":"Eur Heart J"},{"key":"231_CR6","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1517\/14740338.4.3.509","volume":"4","author":"I Cavero","year":"2005","unstructured":"Cavero I, Crumb W (2005) ICH S7B draft guideline on the non-clinical strategy for testing delayed cardiac repolarization risk of drugs: a critical analysis. Expert Opin Drug Saf 4:509\u2013530","journal-title":"Expert Opin Drug Saf"},{"key":"231_CR7","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1038\/sj.bjp.0706070","volume":"144","author":"P Champeroux","year":"2005","unstructured":"Champeroux P, Viaud K, El Amrani AI, Fowler JS, Martel E, Le Guennec JY, Richard S (2005) Prediction of the risk of Torsade de Pointes using the model of isolated canine Purkinje fibres. Br J Pharmacol 144:376\u2013385","journal-title":"Br J Pharmacol"},{"key":"231_CR8","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s00210-005-1063-5","volume":"371","author":"T Christ","year":"2005","unstructured":"Christ T, Wettwer E, Ravens U (2005) Risperidone-induced action potential prolongation is attenuated by increased repolarization reserve due to concomitant block of I(Ca,L). Naunyn Schmiedebergs Arch Pharmacol 371:393\u2013400","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"231_CR9","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1007\/s00210-004-0996-4","volume":"370","author":"T Christ","year":"2004","unstructured":"Christ T, Wust M, Matthes J, Janchen M, Jurgens S, Herzig S, Wettwer E, Dobrev D, Matschke K, Mebs D, Ravens U (2004) An aqueous extract of the marine sponge Ectyoplasia ferox stimulates L-type Ca2+-current by direct interaction with the Cav1.2 subunit. Naunyn Schmiedebergs Arch Pharmacol 370:474\u2013483","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"231_CR10","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/0140-6736(91)90481-4","volume":"338","author":"MJ Connolly","year":"1991","unstructured":"Connolly MJ, Astridge PS, White EG, Morley CA, Cowan JC (1991) Torsades de pointes ventricular tachycardia and terodiline. Lancet 338:344\u2013345","journal-title":"Lancet"},{"key":"231_CR11","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s11934-005-0033-2","volume":"6","author":"R Dmochowski","year":"2005","unstructured":"Dmochowski R, Staskin DR (2005) The QT interval and antimuscarinic drugs. Curr Urol Rep 6:405\u2013409","journal-title":"Curr Urol Rep"},{"key":"231_CR12","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1159\/000020221","volume":"37","author":"W Dorschner","year":"2000","unstructured":"Dorschner W, Stolzenburg JU, Griebenow R, Halaska M, Schubert G, M\u00fcrtz G, Frank M, Wieners F (2000) Efficacy and cardiac safety of propiverine in elderly patients \u2013 A double-blind, placebo-controlled clinical study. Eur Urol 37:702\u2013708","journal-title":"Eur Urol"},{"key":"231_CR13","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1056\/NEJM199103213241201","volume":"324","author":"DS Echt","year":"1991","unstructured":"Echt DS, Liebson PR, Mitchell LB, Peters RW, Obias-Manno D, Barker AH, Arensberg D, Baker A, Friedman L, Greene HL et al (1991) Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med 324:781\u2013788","journal-title":"N Engl J Med"},{"key":"231_CR14","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1007\/s002100000284","volume":"362","author":"H Gogelein","year":"2000","unstructured":"Gogelein H, Bruggemann A, Gerlach U, Brendel J, Busch AE (2000) Inhibition of IKs channels by HMR 1556. Naunyn Schmiedebergs Arch Pharmacol 362:480\u2013488","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"231_CR15","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/BF00656997","volume":"391","author":"OP Hamill","year":"1981","unstructured":"Hamill OP, Marty A, Neher E, Sakmann B, Sigworth FJ (1981) Improved patch-clamp techniques for high-resolution current recording from cells and cell-free membrane patches. Pflugers Arch 391:85\u2013100","journal-title":"Pflugers Arch"},{"key":"231_CR16","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/j.1540-8167.2006.00347.x","volume":"17","author":"LM Hondeghem","year":"2006","unstructured":"Hondeghem LM (2006) Thorough QT\/QTc not so thorough: removes torsadogenic predictors from the T-wave, incriminates safe drugs, and misses profibrillatory drugs. J Cardiovasc Electrophysiol 17:337\u2013340","journal-title":"J Cardiovasc Electrophysiol"},{"key":"231_CR17","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1161\/01.CIR.103.15.2004","volume":"103","author":"LM Hondeghem","year":"2001","unstructured":"Hondeghem LM, Carlsson L, Duker G (2001) Instability and triangulation of the action potential predict serious proarrhythmia, but action potential duration prolongation is antiarrhythmic. Circulation 103:2004\u20132013","journal-title":"Circulation"},{"key":"231_CR18","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1038\/sj.bjp.0702173","volume":"125","author":"SE Jones","year":"1998","unstructured":"Jones SE, Ogura T, Shuba LM, McDonald TF (1998) Inhibition of the rapid component of the delayed-rectifier K+ current by therapeutic concentrations of the antispasmodic agent terodiline. Br J Pharmacol 125:1138\u20131143","journal-title":"Br J Pharmacol"},{"key":"231_CR19","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1097\/00005344-200002000-00024","volume":"35","author":"SE Jones","year":"2000","unstructured":"Jones SE, Kasamaki Y, Shuba LM, Ogura T, McCullough JR, McDonald TF (2000) Analysis of the electrophysiological effects of short-term oxybutynin on guinea pig and rabbit ventricular cells. J Cardiovasc Pharmacol 35:334\u2013340","journal-title":"J Cardiovasc Pharmacol"},{"key":"231_CR20","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/sj.bjp.0703595","volume":"131","author":"SE Jones","year":"2000a","unstructured":"Jones SE, Shuba LM, Zhabyeyev P, McCullough JR, McDonald TF (2000a) Differences in the effects of urinary incontinence agents S-oxybutynin and terodiline on cardiac K+ currents and action potentials. Br J Pharmacol 131:245\u2013254","journal-title":"Br J Pharmacol"},{"key":"231_CR21","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1124\/jpet.103.062182","volume":"308","author":"J Kang","year":"2004","unstructured":"Kang J, Chen XL, Wang H, Ji J, Reynolds W, Lim S, Hendrix J, Rampe D (2004) Cardiac ion channel effects of tolterodine. J Pharmacol Exp Ther 308:935\u2013940","journal-title":"J Pharmacol Exp Ther"},{"key":"231_CR22","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1007\/s003450100223","volume":"19","author":"H Madersbacher","year":"2001","unstructured":"Madersbacher H, M\u00fcrtz G (2001) Efficacy, tolerability and safety profile of propiverine in the treatment of the overactive bladder (non-neurogenic and neurogenic). World J Urol 19:324\u2013335","journal-title":"World J Urol"},{"key":"231_CR23","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1097\/00005344-200403000-00007","volume":"43","author":"RL Martin","year":"2004","unstructured":"Martin RL, McDermont JS, Salmen HJ, Palmatier JD, Cox BF, Gintant GA (2004) The utility of HERG and repolarization assays in evaluating delayed cardiac repolarization: influence of multi-channel block. J Cardiovasc Pharmacol 43:369\u2013379","journal-title":"J Cardiovasc Pharmacol"},{"key":"231_CR24","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1097\/01.fjc.0000246853.15926.d4","volume":"48","author":"RL Martin","year":"2006","unstructured":"Martin RL, Su Z, Limberis JT, Palmatier JD, Cowart MD, Cox BF, Gintant GA (2006) In vitro preclinical cardiac assessment of tolterodine and terodiline: Multiple factors predict the clinical experience. J Cardiovasc Pharmacol 48:199\u2013206","journal-title":"J Cardiovasc Pharmacol"},{"key":"231_CR25","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1136\/bmj.302.6790.1469-c","volume":"302","author":"AA McLeod","year":"1991","unstructured":"McLeod AA, Thorogood S, Barnett S (1991) Torsades de pointes complicating treatment with terodiline. BMJ 302:1469","journal-title":"BMJ"},{"key":"231_CR26","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1111\/j.2042-7158.1997.tb06793.x","volume":"49","author":"P Meisel","year":"1997","unstructured":"Meisel P, Langner S, Siegmund W (1997) In-vitro binding of propiverine hydrochloride and some of its metabolites to serum albumin in man. J Pharm Pharmacol 49:270\u2013272","journal-title":"J Pharm Pharmacol"},{"key":"231_CR27","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s00210-006-0105-y","volume":"374","author":"MC Michel","year":"2006","unstructured":"Michel MC, Hedge SS (2006) Treatment of overactive bladder syndrome with muscarinic receptor antagonists: a matter of metabolites? Naunyn Schmiedebergs Arch Pharmacol 374:79\u201385","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"231_CR28","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1053\/euhj.1998.1220","volume":"20","author":"SG Priori","year":"1999","unstructured":"Priori SG, Barhanin J, Hauer RN, Haverkamp W, Jongsma HJ, Kleber AG, McKenna WJ, Roden DM, Rudy Y, Schwartz K, Schwartz PJ, Towbin JA, Wilde A (1999) Genetic and molecular basis of cardiac arrhythmias; impact on clinical management. Study group on molecular basis of arrhythmias of the working group on arrhythmias of the European society of cardiology. Eur Heart J 20:174\u2013195","journal-title":"Eur Heart J"},{"key":"231_CR29","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/sj.bjp.0706892","volume":"149","author":"S Rajamani","year":"2006","unstructured":"Rajamani S, Eckhardt LL, Valdivia CR, Klemens CA, Gillman BM, Anderson CL, Holzem KM, Delisle BP, Anson BD, Makileski JC, January CT (2006) Drug-induced long QT syndrome: hERG K+ channel block and disruption of protein trafficking by fluoxetine and norfluoxetine. Br J Pharmacol 149:481\u2013489","journal-title":"Br J Pharmacol"},{"key":"231_CR30","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/S0008-6363(02)00846-5","volume":"58","author":"WS Redfern","year":"2003","unstructured":"Redfern WS, Carlsson L, Davis AS, Lynch WG, MacKenzie I, Palethorpe S, Siegl PK, Strang I, Sullivan AT, Wallis R, Camm AJ, Hammond TG (2003) Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc Res 58:32\u201345","journal-title":"Cardiovasc Res"},{"key":"231_CR31","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1161\/01.CIR.94.8.1996","volume":"94","author":"DM Roden","year":"1996","unstructured":"Roden DM, Lazzara R, Rosen M, Schwartz PJ, Towbin J, Vincent GM (1996) Multiple mechanisms in the long-QT syndrome. Current knowledge, gaps, and future directions. The SADS Foundation Task Force on LQTS. Circulation 94:1996\u20132012","journal-title":"Circulation"},{"key":"231_CR32","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1111\/j.1540-8159.1998.tb00148.x","volume":"21","author":"DM Roden","year":"1998","unstructured":"Roden DM (1998) Taking the \"idio\" out of \"idiosyncratic\": predicting torsades de pointes. Pacing Clin Electrophysiol 21:1029\u20131034","journal-title":"Pacing Clin Electrophysiol"},{"key":"231_CR33","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1085\/jgp.96.1.195","volume":"96","author":"MC Sanguinetti","year":"1990","unstructured":"Sanguinetti MC, Jurkiewicz NK (1990) Two components of cardiac delayed rectifier K+ current. Differential sensitivity to block by class III antiarrhythmic agents. J Gen Physiol 96:195\u2013215","journal-title":"J Gen Physiol"},{"key":"231_CR34","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1007\/s002280050549","volume":"54","author":"M Siepmann","year":"1998","unstructured":"Siepmann M, Nokhodian A, Thummler D, Kirch W (1998) Pharmacokinetics and safety of propiverine in patients with fatty liver disease. Eur J Clin Pharmacol 54:767\u2013771","journal-title":"Eur J Clin Pharmacol"},{"key":"231_CR35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1254\/jjp.83.1","volume":"83","author":"J Tamargo","year":"2000","unstructured":"Tamargo J (2000) Drug-induced torsade de pointes: from molecular biology to bedside. Jpn J Pharmacol 83:1\u201319","journal-title":"Jpn J Pharmacol"},{"key":"231_CR36","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1136\/hrt.74.1.53","volume":"74","author":"SH Thomas","year":"1995","unstructured":"Thomas SH, Higham PD, Hartigan-Go K, Kamali F, Wood P, Campbell RW, Ford GA (1995) Concentration dependent cardiotoxicity of terodiline in patients treated for urinary incontinence. Br Heart J 74:53\u201356","journal-title":"Br Heart J"},{"issue":"Suppl 1","key":"231_CR37","doi-asserted-by":"crossref","first-page":"S169","DOI":"10.1111\/j.1540-8167.2006.00401.x","volume":"17","author":"AI Undrovinas","year":"2006","unstructured":"Undrovinas AI, Belardinelli L, Undrovinas NA, Sabbah HN (2006) Ranolazine improves abnormal repolarization and contraction in left ventricular myocytes of dogs with heart failure by inhibiting late sodium current. J Cardiovasc Electrophysiol 17(Suppl 1):S169\u2013S177","journal-title":"J Cardiovasc Electrophysiol"},{"key":"231_CR38","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1038\/sj.bjp.0706244","volume":"145","author":"M Wuest","year":"2005","unstructured":"Wuest M, Hecht J, Christ T, Braeter M, Schoeberl C, Hakenberg OW, Wirth MP, Ravens U (2005) Pharmacodynamics of propiverine and three of its main metabolites on detrusor contraction. Br J Pharmacol 145:608\u2013619","journal-title":"Br J Pharmacol"},{"key":"231_CR39","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s00210-006-0103-0","volume":"374","author":"M Wuest","year":"2006","unstructured":"Wuest M, Weiss A, Waelbrock M, Braeter M, Kelly LU, Hakenberg OW, Ravens U (2006) Propiverine and metabolites: differences in binding to muscarinic receptors and in functional models of detrusor contraction. Naunyn Schmiedebergs Arch Pharmacol 374:87\u201397","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"231_CR40","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1161\/01.RES.84.9.989","volume":"84","author":"S Zhang","year":"1999","unstructured":"Zhang S, Zhou Z, Gong Q, Makielski JC, January CT (1999) Mechanism of block and identification of the verapamil binding domain to HERG potassium channels. Circ Res 84:989\u2013998","journal-title":"Circ Res"},{"key":"231_CR41","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S0006-3495(98)77782-3","volume":"74","author":"Z Zhou","year":"1998","unstructured":"Zhou Z, Gong Q, Ye B, Fan Z, Makielski JC, Robertson GA, January CT (1998) Properties of HERG channels stably expressed in HEK 293 cells studied at physiological temperature. Biophys J 74:230\u2013241","journal-title":"Biophys J"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-007-0231-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00210-007-0231-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-007-0231-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T20:02:13Z","timestamp":1558641733000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00210-007-0231-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,12,19]]},"references-count":41,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2008,2]]}},"alternative-id":["231"],"URL":"https:\/\/doi.org\/10.1007\/s00210-007-0231-1","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,12,19]]}}}